Ingredion: Why I Moved INGR From Watch to Fail in Two Weeks

← All Articles

Rating: FAIL (avoid on the Graham criteria). Two weeks ago, I called Ingredion (NYSE: INGR) a WATCH after its bid for Tate & Lyle tripled the company's pro forma leverage. This week the same screen moved it to FAIL. What's unusual is why: the stock did not get more expensive. On the raw numbers it still looks cheap. It failed anyway, on a rule I built specifically to stop me from buying a company that is about to stop being the company I underwrote. Here is exactly what changed, and where I got the first call wrong.

The number still says "cheap," which is the trap

Start with what has not changed. At $98.57, INGR carries a Graham Number of $125.86, a 22% margin of safety. It trades at a P/E of 9.6, a price-to-book of 1.42 against book value of $69.30 per share, and a current ratio of 2.66, with a three-year average EPS of $10.16 anchoring the Graham Number. Add a 29-year run of consecutive dividend payments and an adjusted ROIC of 15.5%, and this is, on its face, exactly the kind of dull, solvent, reasonably-priced business Benjamin Graham's Enterprising Investor screen is designed to surface.

That is precisely the problem, and the reason this article exists. A margin of safety is only as good as the earnings and balance sheet it is measured against. The $125.86 Graham Number is computed from trailing normalized earnings and today's book value, a company with net leverage under 1x, before it writes a $5 billion check. The screen is telling me the past version of Ingredion was worth more than the market pays. It is silent on the version that exists after the deal closes. The 22% cushion is real, but it is priced against a company that is on its way out of existence in its current form.

Before the deal: a clean PASS

When I first ran INGR through the screen this quarter, it passed cleanly. Sub-10 P/E. Current ratio of 2.66, comfortably above Graham's 2.0 threshold. Net debt under one turn of EBITDA. Twenty-nine straight years of dividends, the kind of earnings stability Graham weighted heavily. There was nothing to argue with. It was a textbook enterprising-investor candidate: unglamorous, financially conservative, and trading below intrinsic value.

After the announcement: WATCH

On June 8, 2026, Ingredion announced a recommended all-cash offer to acquire Tate & Lyle PLC, a direct competitor in texturants and specialty ingredients, for roughly $3.6 billion in equity value, or close to $5.0 billion on an enterprise-value basis at the offer's 595-pence-per-share terms, a ~59% premium (company release). On June 24 the company secured a $1.475 billion delayed-draw term loan to help fund it (TipRanks). That facility on its own would more than double existing long-term debt of $1.742 billion.

Management guided to pro forma net leverage of roughly 3.0x net-debt-to-EBITDA at completion, with a stated plan to bring that back toward 2.5x within about 18 months, and reaffirmed its investment-grade commitment (8-K). The dividend was left intact which I thought was a good indication that management was in control. Completion is not expected until the second half of 2027.

So, I called it a WATCH. The deal roughly triples net leverage, from under 1x to about 3x, but the quantitative screen still cleared, the dividend signal was strong, and management had a credited deleveraging path. WATCH felt like the disciplined middle.

Why it's a FAIL now

Here is where the rule does its job. GrahamGrade's hard gates are not just the classic P/E, P/B, and current-ratio thresholds. They include a material-event gate: a transforming, debt-funded acquisition worth a large share of market capitalization automatically fails, regardless of how cheap the trailing multiples look. Tate & Lyle is about 58% of Ingredion's market cap, funded by new debt that doubles the balance sheet. It trips that gate.

I want to be precise, because the mechanism matters. INGR did not fail because its Graham Number fell below the market price. It didn't: the 22% margin of safety is still there on the screen. It failed because the margin of safety is measured on a company that is being deliberately dismantled and rebuilt with three times the leverage. The rule overrides the number on purpose. That is the whole point of having it: to stop a backward-looking valuation from waving through a forward-looking balance-sheet change it cannot see.

What I got wrong the first time

The WATCH call was a mistake, and the information to avoid it was already public. When Ingredion reported Q1 2026, adjusted EPS came in at $2.34 against a $2.97 prior-year quarter and a $2.47 consensus, a 5.3% miss, while reported EPS fell to $2.22 from $3.00 (Q1 release). Management cut full-year adjusted EPS guidance to $10.45–$11.15, a 5.3% reduction at the midpoint, citing operational disruption at its Argo facility, FX pressure, and softer Latin American demand.

I had all of that when I wrote WATCH and I underweighted it. I leaned on the intact dividend and the 29-year streak as the dominant stability signal and treated the base business as steady enough to carry the added leverage. What I missed is that the base business was softening at the exact moment leverage was set to triple. A deleveraging plan that takes net debt from 3.0x to 2.5x over 18 months is underwritten by forward earnings, and those earnings had just been guided down. A safe dividend today is not the same thing as a durable Graham margin of safety through a levered integration. Conflating the two is how a WATCH should have been a FAIL from the start.

What stays constant

None of this is a judgment on whether the Tate & Lyle deal is good corporate strategy; it may very well be. It is a statement about whether INGR belongs in a Graham portfolio right now, and it doesn't. The value of a rules-based screen is that it reaches the same verdict whether or not I've talked myself into a story. My WATCH call was the story, while the gate was the rule. When the two disagree, the rule is supposed to win, and this time it caught something my judgment had waved through.

That's the discipline I'm paying for when I run this screen, and it's the discipline I owe anyone reading it: when the numbers move a rating, we report the move, including when it corrects me.

Risks to this call

Two things could make the FAIL look overly cautious in hindsight. First, if the deal fails to complete (UK scheme-of-arrangement transactions face shareholder and regulatory conditions, and completion is more than a year out), the leverage thesis evaporates and INGR reverts to the clean pre-deal profile that passed. Second, if management executes the deleveraging faster than guided and the acquired texturants business lifts margins, the combined entity could re-enter the screen at an attractive multiple within a couple of years. The gate is a stop sign, not a permanent verdict; it re-evaluates every cycle.